SVRA: MOLBREEVI MAAs Under Review
Savara says MOLBREEVI MAAs are under review by EMA and U.K.'s MHRA
’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041